{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:42:48Z","timestamp":1767148968815,"version":"build-2238731810"},"reference-count":73,"publisher":"Elsevier BV","issue":"15","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.purol.2013.09.020","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T12:16:48Z","timestamp":1382617008000},"page":"1271-1286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Les m\u00e9dicaments de la vessie"],"prefix":"10.1016","volume":"23","author":[{"given":"R.","family":"Caremel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-N.","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kerdraon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Castel-Lacanal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bastide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bruyere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Karsenty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2013.09.020_bib0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0094-0143(21)00501-2","article-title":"Anatomy and physiology of the lower urinary tract","volume":"20","author":"de Groat","year":"1993","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.purol.2013.09.020_bib0010","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.eururo.2009.07.044","article-title":"A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature","volume":"56","author":"Roosen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/nau.21246","article-title":"Mechanisms of action of botulinum neurotoxins, beta3-adrenergic receptor agonists, and PDE5\u00a0inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011","volume":"31","author":"Kanai","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2013.09.020_bib0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","article-title":"Antimuscarinic mechanisms and the overactive detrusor: an update","volume":"59","author":"Andersson","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0025","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","article-title":"A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder","volume":"54","author":"Novara","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0030","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1742-1241.2010.02611.x","article-title":"Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review","volume":"65","author":"Kaplan","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.purol.2013.09.020_bib0035","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0040","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","article-title":"Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis","volume":"62","author":"Madhuvrata","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0045","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.purol.2013.09.020_bib0050","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/S1166-7087(10)70003-8","article-title":"[Guidelines for the medical treatment of non-neurological urinary incontinence in women]","volume":"20","author":"Conquy","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0055","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.eururo.2012.08.047","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"62","author":"Lucas","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0060","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.purol.2012.10.001","article-title":"[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association]","volume":"22","author":"Descazeaud","year":"2012","journal-title":"Progn Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","volume":"64","author":"Oelke","year":"2013","journal-title":"Euro Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0070","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.sc.3100750","article-title":"Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia\u2013a double-blind, placebo-controlled clinical trial","volume":"37","author":"Stohrer","year":"1999","journal-title":"Spinal Cord"},{"key":"10.1016\/j.purol.2013.09.020_bib0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2009.04.028","article-title":"EAU guidelines on neurogenic lower urinary tract dysfunction","volume":"56","author":"Stohrer","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0080","first-page":"225","article-title":"The cognitive impact of anticholinergics: a clinical review","volume":"4","author":"Campbell","year":"2009","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.purol.2013.09.020_bib0085","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1532-5415.2011.03491.x","article-title":"Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study","volume":"59","author":"Fox","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.purol.2013.09.020_bib0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11597530-000000000-00000","article-title":"Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder","volume":"29","author":"Chancellor","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.purol.2013.09.020_bib0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","article-title":"Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR Study","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3\u00a0trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0105","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3\u00a0study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0115","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.eururo.2010.07.026","article-title":"Nitric oxide\/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat","volume":"58","author":"Caremel","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0120","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2012.09.006","article-title":"The mechanism of action of phosphodiesterase type 5\u00a0inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia","volume":"63","author":"Giuliano","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0125","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.juro.2006.10.055","article-title":"Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial","volume":"177","author":"McVary","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0130","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.eururo.2008.01.075","article-title":"A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"53","author":"Stief","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0135","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","article-title":"Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial","volume":"61","author":"Oelke","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0140","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","article-title":"A systematic review and meta-analysis on the use of phosphodiesterase 5\u00a0inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"61","author":"Gacci","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0145","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jsm.12039","volume":"10","author":"Giuliano","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.purol.2013.09.020_bib0150","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2012.01.051","article-title":"Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity","volume":"61","author":"Behr-Roussel","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0155","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin A","volume":"342","author":"Schurch","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.purol.2013.09.020_bib0160","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs. Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0165","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0170","first-page":"CD005493","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","author":"Duthie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.purol.2013.09.020_bib0175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","article-title":"Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"53","author":"Karsenty","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0180","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0185","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.eururo.2007.08.052","article-title":"Do repeat intradetrusor botulinum toxin type a injections yield valuable results. Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity","volume":"52","author":"Reitz","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0190","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.purol.2012.10.006","article-title":"Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity","volume":"22","author":"Gaillet","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0195","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2013.09.020_bib0200","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","article-title":"Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder","volume":"186","author":"Giannantoni","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0205","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.urology.2005.08.016","article-title":"Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions","volume":"67","author":"Kuo","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.020_bib0210","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jpurol.2009.01.005","article-title":"Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review","volume":"5","author":"Game","year":"2009","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0215","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"Onabotulinumtoxin A 100\u00a0U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0220","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxin A for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0225","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/nau.20946","article-title":"A pilot study of botulinum toxin for interstitial cystitis\/painful bladder syndrome","volume":"30","author":"Gottsch","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2013.09.020_bib0230","first-page":"109","article-title":"Intravesical botulinum toxin A injections do not benefit patients with ulcer type interstitial cystitis","volume":"16","author":"Lee","year":"2013","journal-title":"Pain Physician"},{"key":"10.1016\/j.purol.2013.09.020_bib0235","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.juro.2012.09.027","article-title":"Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome\/interstitial cystitis","volume":"189","author":"Pinto","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0240","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.juro.2011.03.064","article-title":"AUA guideline for the diagnosis and treatment of interstitial cystitis\/bladder pain syndrome","volume":"185","author":"Hanno","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0245","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2007.08.039","article-title":"Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections","volume":"53","author":"Game","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0250","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","article-title":"Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: an ESSIC proposal","volume":"53","author":"van de Merwe","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0255","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1016\/j.febslet.2007.06.058","article-title":"p53\u00a0mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells","volume":"581","author":"Kim","year":"2007","journal-title":"FEBS Lett"},{"key":"10.1016\/j.purol.2013.09.020_bib0260","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.juro.2009.12.106","article-title":"Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis\/painful bladder syndrome","volume":"183","author":"Foster","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0265","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/01.ju.0000132388.54703.4d","article-title":"A prospective, randomized, placebo-controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis","volume":"172","author":"van Ophoven","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0270","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/01.ju.0000176741.10094.e0","article-title":"Long-term results of amitriptyline treatment for interstitial cystitis","volume":"174","author":"van Ophoven","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0275","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1464-410x.2001.02031.x","article-title":"Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial","volume":"87","author":"Thilagarajah","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2013.09.020_bib0280","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0022-5347(17)41478-9","article-title":"A controlled study of dimethyl sulfoxide in interstitial cystitis","volume":"140","author":"Perez-Marrero","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0285","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0090-4295(93)90198-J","article-title":"Prolongation of response to DMSO by heparin maintenance","volume":"41","author":"Perez-Marrero","year":"1993","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.020_bib0290","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.juro.2012.06.023","article-title":"Cyclosporine A for refractory interstitial cystitis\/bladder pain syndrome: experience of 3\u00a0tertiary centers","volume":"188","author":"Forrest","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0295","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1097\/01.ju.0000181808.45786.84","article-title":"Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study","volume":"174","author":"Sairanen","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0300","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/0090-4295(90)80116-5","article-title":"Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study","volume":"35","author":"Mulholland","year":"1990","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.020_bib0305","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0022-5347(17)43243-5","article-title":"Successful therapy of interstitial cystitis with pentosanpolysulfate","volume":"138","author":"Parsons","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0310","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0022-5347(17)43241-1","article-title":"A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease","volume":"138","author":"Holm-Bentzen","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0315","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/01.ju.0000083020.06212.3d","article-title":"A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis","volume":"170","author":"Sant","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0320","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1464-410X.1997.03384.x","article-title":"A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis","volume":"79","author":"Bade","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0325","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00192-008-0560-8","article-title":"The effects of intravesical pentosanpolysulfate treatment on the symptoms of patients with bladder pain syndrome\/interstitial cystitis: preliminary results","volume":"19","author":"Daha","year":"2008","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.purol.2013.09.020_bib0330","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/nau.21097","article-title":"Detrusor underactivity: a plea for new approaches to a common bladder dysfunction","volume":"30","author":"van Koeveringe","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.purol.2013.09.020_bib0335","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1464-410X.2006.06742.x","article-title":"Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based","volume":"99","author":"Barendrecht","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2013.09.020_bib0340","first-page":"CD002238","article-title":"Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics)","volume":"12","author":"Deshpande","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.purol.2013.09.020_bib0345","first-page":"CD002112","article-title":"Desmopressin for nocturnal enuresis in children","author":"Glazener","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.purol.2013.09.020_bib0350","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2011.05.065","article-title":"Nocturia and quality of life: results from the Boston area community health survey","volume":"61","author":"Kupelian","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0355","first-page":"502","article-title":"[Role of estrogens in lower urinary tract physiology and physiopathology]","volume":"23","author":"Game","year":"2013","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2013.09.020_bib0360","first-page":"CD001405","article-title":"Oestrogen therapy for urinary incontinence in post-menopausal women","volume":"10","author":"Cody","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.purol.2013.09.020_bib0365","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.maturitas.2010.11.013","article-title":"Management of menopausal symptoms in breast cancer patients","volume":"68","author":"Loibl","year":"2011","journal-title":"Maturitas"}],"updated-by":[{"DOI":"10.1016\/j.purol.2013.11.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000}}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708713007069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708713007069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T08:53:38Z","timestamp":1646902418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708713007069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":73,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1166708713007069"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2013.09.020","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les m\u00e9dicaments de la vessie","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2013.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}